Radiotherapy is one of the mainstays of anticancer treatment, but the relationship between the radiosensitivity of cancer cells and their genomic characteristics is still not well defined. Here, we report the development of a high-throughput platform for measuring radiation survival in vitro and its validation in comparison with conventional clonogenic radiation survival analysis. We combined results from this high-throughput assay with genomic parameters in cell lines from squamous cell lung carcinoma, which is standardly treated by radiotherapy, to identify parameters that predict radiation sensitivity. We showed that activation of NFE2L2, a frequent event in lung squamous cancers, confers radiation resistance. An expression-based, in silico screen nominated inhibitors of phosphoinositide 3-kinase (PI3K) as NFE2L2 antagonists. We showed that the selective PI3K inhibitor, NVP-BKM120, both decreased NRF2 protein levels and sensitized NFE2L2 or KEAP1-mutant cells to radiation. We then combined results from this high-throughput assay with single-sample gene set enrichment analysis of gene expression data. The resulting analysis identified pathways implicated in cell survival, genotoxic stress, detoxification, and innate and adaptive immunity as key correlates of radiation sensitivity. The integrative and high-throughput methods shown here for large-scale profiling of radiation survival and genomic features of solid-tumor–derived cell lines should facilitate tumor radiogenomics and the discovery of genotype-selective radiation sensitizers and protective agents. Cancer Res; 73(20); 6289–98. ©2013 AACR.
The use of a combination of radio- and chemotherapy, or chemoradiation, is the mainstay of treatment of many solid malignancies (1). In recent years, the use of cancer chemotherapeutic drugs has increasingly been driven by genomic characteristics, especially for targeted therapies (2–4). In contrast, despite correlative studies that have established gene classifiers predictive of radiation response across the NCI-60 panel of cell lines (5–7), there have not been extensive systematic analyses of the correlation between radiation sensitivity and genomic parameters.
In 1956, Puck and Marcus described a technique for assessment of clonogenic growth of HeLa cells after exposure to radiation in vitro (8). The clonogenic assay is still widely considered the most reliable in vitro assay for assessing toxicity in cell lines, measuring the sum of all modes of cell death while simultaneously accounting for delayed growth arrest. Unlike cellular response to cytotoxic compounds, most cells lethally damaged by radiation do not immediately cease proliferation but may multiply for several generations before terminating reproduction (9). Therefore, short-term assays that are useful for the study of cytotoxic compounds have not proven effective in accurately profiling solid-tumor–derived cell survival after exposure to radiation.
Although several high-throughput screening assays that measure cellular response to DNA double-strand breaks have been used effectively to identify modulators of DNA damage response (10, 11), such pathway-focused assays lack the scope needed for a comprehensive evaluation of the physiologic and genomic parameters influencing survival following exposure to radiation. The lack of a high-throughput assay measuring clonogenic survival is a major obstacle in radiobiology research. Such an assay could facilitate large-scale studies to identify predictive markers for tumor response to therapy and facilitate development of rational combinatorial (chemoradiation) treatment. Several radiosensitizing drugs are currently used clinically, but despite their shown efficacy, they have numerous shortcomings (12, 13). In particular, their efficacy and toxicity are likely to vary based on the genetic characteristics of individual tumors, significantly limiting their optimal use. Recent studies have identified frequent and targetable genomic alterations that are correlated with the likelihood of response to specific agents, particularly for lung cancer (2–4). Similar studies are desperately needed to discover promising targets for agents that increase the radiotherapeutic ratio.
Herein, we report on a high-throughput platform that measures radiation survival and leverages cancer genomic data to advance knowledge of radiation tumor biology and therapeutic possibilities.
Materials and Methods
Cell culture and irradiation
Lung squamous cell carcinoma (SCC) cell lines from the Cancer Cell Line Encyclopedia (CCLE) were authenticated as per CCLE protocol (14) and grown in recommended media supplemented with 10% FBS (Benchmark) and 100 U/mL penicillin, 100 μg/mL of streptomycin, and 292 μg/mL l-glutamine (Corning). All cultures were maintained at 37°C in a humidified 5% CO2 atmosphere and tested to ensure absence of Mycoplasma. Plates were treated with 0 Gy (no radiation) or with 1 to 10 Gy of γ-radiation delivered at 0.91 Gy/min with a 137Cs source using a GammaCell 40 Exactor (Best Theratronics).
Cells were plated at appropriate dilutions, irradiated, and incubated for 10 to 14 days for colony formation. For chemical radiosensitization measurements, drug was added 24 hours before irradiation. Colonies were fixed in a solution of acetic acid and methanol 1:3 (v/v) and stained with 0.5% (w/v) crystal violet as previously described (15). A colony was defined to consist of 50 cells or more. Colonies were counted digitally using ImageJ software as described previously (16). Integration of survival as a function of dose, or area under the curve, was calculated using Prism, GraphPad Software.
High-throughput proliferation assay
Cells were plated using a Multidrop Combi liquid handler (Thermo Fisher) in quadruplicates for each time point at four cell densities (range, 25–300 cells/well) in a white 384-well plate (Corning). Plates were irradiated and at each time point, media was aspirated and 40 μL of CellTiter-Glo reagent (50% solution in PBS; Promega) was added to each well. Relative luminescence units (RLU) were measured using an Envision multilabel plate reader (PerkinElmer) with a measurement time of 0.1 seconds. Luminescence signal is proportional to the amount of ATP present.
Antibody and reagents
Anti-NRF2 antibody (ab31163) was from Abcam (17). NVP-BKM120 and TGX-221 was from Selleck. LY 294002 was from Cell Signaling Technology.
RNA interference analysis and generation of LC-1/SQSF, hNQO1-ARE-luc
Construction of the retroviral expression vector of short hairpin RNA (shRNA) was carried out as described previously (18). The shRNA-targeted sequences were as follows: NRF2-1 shRNA, AGAGCAAGATTTAGATCATTT; NRF2-2 shRNA, GCTCCTACTGTGATGTGAAAT. The control vector contains nontargeting shRNA sequence. The entry vectors were recombined with pLKO-Tet-ON-puro by LR reactions (Invitrogen, in accordance with the manufacturer's instructions. After infection (multiplicity of infection > 1), cells were selected and maintained in the presence of 1 μg/mL puromycin.
LC-1/SQSF, hNQO1-ARE-luc cells were produced as follows. hQR41-ARE sequence (19) and firefly luciferase-PEST sequence (Promega) were cloned into plenti6/BLOCK-iT-DEST lentivirus backbone (Invitrogen) at the restriction sites of NcoI and HindIII. The engineered region was sequence-verified and matched 100% of the expected sequences. The plasmid was stably infected to the LC-1/SQSF cell line, selected, and maintained in 5 μg/mL Blasticidin in the recommended media.
TP53 and NFE2L2 pathway signatures
Gene transcription signature of pathways TP53 (or p53) and NFE2L2 (or NRF2) were defined as described previously (20; see Supplementary Data).
Single-sample gene set enrichment analysis and the information-based association metric
The single-sample gene set enrichment analysis (ssGSEA) enrichment scores were obtained as described previously (see Supplementary Data).
Development and validation of a high-throughput radiation survival assay
To profile radiation response in lung SCC cell lines, we conducted clonogenic assays on 18 lines after exposure to 0, 2, 5, or 8 Gy of γ-rays. LOU-NH91 and SK-MES-1 were nonclonogenic and SW1573 had prohibitively low plating efficiencies. We were therefore able to analyze survival for 15 of 18 available cell lines (Supplementary Fig. S1; Supplementary Table S1).
We measured radiation response in the same 18 cell lines in a format amenable to high-throughput profiling. We first optimized growth measurements in 384-well plates. The linear range for proliferation as a function of cell density was determined for each cell line; representative plots and light microscopy images for LUDLU-1 and EBC-1 after incubation for 9 days are shown in Supplementary Fig. S2A and S2C. Using cell densities in the linear range of plating, we assessed growth (0 Gy) and recovery of growth after exposure to a range of doses of radiation by plotting RLUs as a function of time (Supplementary Fig. S2B).
The proliferating fraction (mean RLU at dose x/mean RLU of control) was plotted as a function of dose at 9 days for all cell lines (Supplementary Fig. S2D; Supplementary Table S2). We next examined whether the high-throughput platform correlated with clonogenic survival following exposure to radiation. We assessed the extent of correlation between individual doses (for each cell line, n ≥ 2). R2 values were calculated using the average value for each cell line by comparing surviving fraction at dose x (SFx) with proliferating fraction at dose x (PFx), generating a correlation table across the different doses of radiation (Fig. 1A). These data indicate that high-throughput proliferation better approximates clonogenic assay measurements at doses greater than 2 Gy. Among the PFx doses, R2 values were highest for PF4. Therefore, the dose that best approximates clonogenic survival is within the GI50 range for all cell lines (3–5 Gy).
For each proliferation and clonogenic experiment carried out, we integrated survival as a function of dose and generated values for each cell line. Mean integral survival for 15 cell lines (for each cell line, n ≥ 2) was calculated and compared with values from the clonogenic assay (Fig. 1B). Proliferation and colony integral survival values were significantly correlated, with Pearson r = 0.90, R2 = 0.80, and P < 0.0001. Linear regression showed a slope of 0.73 ± 0.1.
We next assessed correlation between clonogenic survival and the high-throughput platform as a function of time (Fig. 1C). The concordance between clonogenic survival and proliferation after radiation exposure is time dependent, reaching statistical significance on day 8 and achieving the highest correlation on day 9 (Fig. 1C).
In addition to squamous cell lung carcinoma cell lines, we assayed a broader diversity of lung cancer cell lines for radiation response and found that the results of the high-throughput platform shown here are broadly consistent with the literature across multiple lung cancer cell types (21, 22; Supplementary Fig. S3). Taken together, these results indicate that the high-throughput platform facilitates the profiling of cell lines for radiation response and, despite some differences between the two assays, closely approximates clonogenic survival by most radiation response parameters.
NFE2L2 activation regulates radiation resistance in lung SCC
NFE2L2 and KEAP1 are key regulators of oxidative and electrophilic stress response (23, 24). Exposure to reactive oxygen species (ROS) directly modifies cysteine residues in KEAP1, leading to NRF2 stabilization and translocation into the nucleus. NRF2 is responsible for the activation of cytoprotective genes, including genes that scavenge ROS (25, 26). Indeed, NRF2 activity has been shown to confer both radiation resistance and lower endogenous levels of ROS (27, 28).
The extent to which NRF2 mediates therapeutic resistance has yet to be fully assessed across a large panel of cell lines or in lung SCC. We sought to assess NRF2′s role as a regulator of radiation resistance in lung SCC cell lines. We first computed a summary gene signature score for NRF2 activation (see Materials and Methods and Supplementary Data) for each cell line profiled and determined the extent of correlation with radiation response. Survival after radiation exposure was significantly correlated with NRF2 score, with Pearson r = 0.47, R2 = 0.22, and P = 0.047 (Fig. 2A). Directed sequencing of NFE2L2 and KEAP1 revealed a high frequency of alterations in lung SCC cell lines (Supplementary Table S3). We then stratified radiation response by mutation and high NRF2 score, defined as a value greater than the median (0.10; Fig. 2B). These data showed that high NRF2 score is a good predictor of radiation resistance.
Disruption of the KEAP1 binding sites within NRF2 (L23WRQDIDLG and D77EETGE; Fig. 2C) have been previously shown to decrease NRF2-KEAP1 binding, inhibit KEAP1-mediated degradation, and ultimately promote transcriptional activity of NRF2 (29). Consistent with these results, both NFE2L2-mutant LC-1/SQSF (NRF2 score, 0.27) and KEAP1-mutant HCC15 (NRF2 score, 0.26) cell lines showed greater NRF2 protein levels compared with NFE2L2/KEAP1 wild-type cell line RERF-LC-AI (NRF2 score, 0.10; Fig. 2D). The magnitude of NRF2 stabilization in LC-1/SQSF and HCC15 approximated that observed for RERF-LC-AI cells treated with tert-butylhydroquinone (tBHQ), a chemical promoter of NRF2 stabilization and transcriptional activity (30).
To determine the role of NRF2 in regulating radiation response, we established LC-1/SQSF cells that stably express shRNAs against NRF2. Two lentiviral-inducible NRF2-targeted shRNAs (shNRF2-1 and shNRF2-2) significantly reduced the expression of endogenous mutant NRF2 compared with control shNTC (Fig. 2E). We tested clonogenic survival after lentiviral-induction in cells that stably expressed shNTC, shNRF2-1, and shNRF2-2. Cells that stably expressed shNRF2-2 had significantly diminished clonogenic capacity, correlating with the extent of reduced NRF2 protein, and therefore could not be evaluated for radiation response (Fig. 2F). To determine whether NRF2 has a role in resistance to radiation, we treated shNTC and shNRF2-1–infected LC-1/SQSF cells with radiation and then examined their clonogenic survival. NRF2-downregulated cells were more sensitive to radiation than control cells (Fig. 2G). It is important to note that this experiment models single-fraction treatment. Patients generally receive multiple fractions of treatment, with a predicted compounding of the sensitization effect.
To determine whether NRF2 has a role in radiation resistance in a cell line that does not contain activating mutations in NFE2L2 or KEAP1, we established RERF-LC-AI cells that stably express shRNAs against NRF2. shNRF2-1 had a minimal affect on NRF2 protein level, whereas shNRF2-2 significantly reduced the expression of endogenous NRF2 compared with control shNTC (Fig. 2H). In contrast to the diminished clonogenic capacity and radiosensitivity phenotype observed in LC-1/SQSF, significant reduction of NRF2 in RERF-LC-AI did not result in any observable decrease in clonogenic capacity or radiation sensitivity (Fig. 2I and J). Taken together, these data indicate that mutation and activation of the NFE2L2 pathway confer radiation resistance in lung SCC.
To determine the extent of activation of NFE2L2 across multiple tumor types, we computed a summary gene signature score for NRF2 activation for each cell line in the CCLE (967 cell lines; Supplementary Fig. S4). This indicates that activation of NRF2 is not unique to specific tumor lineages and nominates it as radiotherapeutic target in a wide range of malignancies.
Phosphoinositide 3-kinase inhibitors are NRF2 antagonists and radiation sensitizers
Multiple in silico approaches of high-throughput discovery have emerged, including the Connectivity Map (cmap), a Web-based tool that comprises a large gene expression database generated from human cancer cell lines treated with different chemicals (31, 32). Several studies have shown the use of chemical genomics in modulating biologic processes by querying gene expression patterns (33–38). We screened for compounds whose expression negatively correlates with the NFE2L2 signature. The results of the screen are listed by rank order using a matching algorithm based on the nonparametric rank-ordered Kolmogorov–Smirnov statistics transformed to a “connectivity score” ranging from +1 to −1 (Fig. 3A). A negative score denotes a negative correlation between a query signature and an individual chemical, indicating that the phosphoinositide 3-kinase (PI3K) inhibitors genistein, LY 294002, and wortmannin are putative NRF2 antagonists (see Fig. 3B for a “bar view” of individual cmap instances).
Expression of active PI3K has long been implicated in regulating therapeutic (chemical and radiation) resistance (39, 40), although the precise mechanism(s) of resistance remain poorly defined. NRF2 has previously been shown to require cooperation from active PI3K-Akt signaling (41). These results, coupled with the in silico findings earlier, suggested that PI3K-Akt inhibition may be an effective strategy to antagonize NRF2 and by extension effect radiosensitization. To test this, we first established LC-1/SQSF cells that stably express hNQO1-ARE-luc, containing cis-acting antioxidant response regulatory elements in the 5′-flanking region of NAD(P)H:quinone oxidoreductase (NQO1; ref. 19), a gene induced by NRF2. We measured luciferase activity in LC-1/SQSF, hNQO1-ARE-luc cells after incubation with LY 294002, NVP-BKM120, or TGX-221. The pan-PI3K inhibitors LY 294002 and NVP-BKM120, but not the PI3Kβ selective inhibitor TGX-221, resulted in a significant decrement in NRF2 activity (Fig. 3C, top). We measured cellular viability after incubation with LY 294002, NVP-BKM120, or TGX-221. The decrement in cellular viability at 48 hours (Fig. 3C, bottom) mirrored the effect on NRF2 activity at 24 hours. This correlation between viability and NRF2 activity suggests that either LC-1/SQSF cells are dependent on NRF2 for viability (suggested by Fig. 2F) or that toxicity leads to a nonspecific decrement in NRF2 activity.
To address this, we measured NRF2 protein level in the same cells after incubation with LY 294002, NVP-BKM120, or TGX-221 at 24 hours, an interval of time that showed a negligible decrement in viability (viability > 90%). Consistent with the reporter assay, LY 294002 and NVP-BKM120, but not TGX-221, resulted in a significant decrement in NRF2 protein level (Fig. 3D). NVP-BKM120 resulted in a similar decrement in NRF2 protein level for HCC15 and RERF-LC-AI cells treated with tBHQ. These results indicate that an active PI3K pathway is required for NRF2 stability and that the putative target for NRF2 antagonism is PI3K through isoforms other than PI3Kβ.
Because NRF2 downregulation affects radiosensitization in LC-1/SQSF cells (Fig. 2), and NVP-BKM120 results in NRF2 downregulation, we predicted that NVP-BKM120 can function as a radiation sensitizer in cell lines with an active NRF2 pathway. LC-1/SQSF, HCC15, and A549 cells exposed to NVP-BKM120 and radiation showed a synergistic decrement in clonogenic survival compared with control (0 Gy) cells (Fig. 4). RERF-LC-AI and SQ-1 (NFE2L2 and KEAP1 wild-type) cells showed significantly less synergy between NVP-BKM120 and radiation. These results indicate that treatments that antagonize NRF2-mediated transcription can be potent radiation sensitizers and suggest that the synergy between PI3K inhibitors and radiation are greater in cell lines with an active NRF2 pathway.
Gene expression analysis identifies pathways that correlate with radiation response in lung SCC
Susceptibility of tumors to radiation is regulated by several pathways mediating the cellular response to radiation-induced damage. To identify pathways that are differentially correlated with radiation response, we used ssGSEA projection (42) as a hypothesis-generating gene set identification tool.
ssGSEA identifies biologically relevant gene sets that correlate with a functional output by estimating the degree to which an established gene set is overrepresented at the top or bottom of the sorted gene expression values list in each sample. To achieve this, we calculated an ssGSEA enrichment score, which is based on the weighted difference of the Empirical Cumulative Distribution Functions of the genes in the set relative to the genes not included in an individual set (42). The result is a single score per cell line per gene set, transforming the original dataset into a more interpretable higher-level description. Gene sets were obtained from the C2 sub-collection of the Molecular Signatures database (MsigDB; ref. 43), an additional collection of oncogenic signatures, and other cancer-related gene sets curated from the literature, resulting in a dataset that has 4,628 pathway profiles for each sample. The association between the ssGSEA profiles for each gene set and the radiation response profile is then determined using an information-based similarity metric (RNMI; see Materials and Methods and Supplementary Data) and the dataset is resorted on the basis of this metric to identify correlates and anticorrelates with radiation survival (Fig. S5 and S6).
We first compared the profiles of each gene set/pathway with the radiation response scores (integral survival by clonogenic assay and high-throughput platform). The ssGSEA scores are displayed in a heatmap with the top 15 gene sets that correlate and anticorrelate with radiation survival (Supplementary Fig. S5 and Table S3). Analysis of the both the top 15 and top 50 gene sets (Supplementary Fig. S5 and S6) revealed overlap in the gene sets identified by the clonogenic assay and high-throughput platform. Moreover, we inserted the calculated ssGSEA enrichment scores using the NRF2 gene set and identified NRF2 activation as positively correlated with radiation resistance; the NRF2 gene set was ranked number 48 using survival data from the high-throughput platform. These results indicate that ssGSEA is a robust gene set identification tool.
An analysis of the gene sets that is differentially correlated with radiation survival suggested that pathways implicated in cell survival, genotoxicity, detoxification, and innate or adaptive immunity can regulate radiation response. Moreover, the identity of individual gene sets and their correlation with radiation response can identify and aid in the validation of targets for potential radiotherapeutic sensitization. For example, a TP53 gene set was identified by ssGSEA [rank number seven in the high-throughput platform analysis (Supplementary Fig. S5 and S6)], suggesting that TP53 transcriptional activation mediates radiation resistance. Despite a well-defined role for TP53 in regulation of DNA repair, cell-cycle arrest, and apoptosis after genotoxic stress (44), the predictive role of TP53 mutations in radiation response has been uncertain.
Beyond showing a proof-of-concept that ssGSEA can identify known regulators of radiation response, we sought to lend clarity to the role of alterations in TP53 on radiation response across a panel of cell lines. We first assessed TP53 mutations, LOH, and mRNA levels in the lung SCC cell lines profiled for radiation response (Supplementary Table S4). TP53 is frequently altered in the lung SCC cell lines; eight of 18 cell lines having missense mutations, all of which cluster in the DNA-binding domain (amino acids, 101–305). We compared TP53 mRNA levels as a function of genotype and found a significant difference in mRNA levels in cell lines with nondisruptive (missense mutation and intronic insertion) versus disruptive (nonsense mutation and deletion) alterations (P < 0.0001; Supplementary Fig. S7A). We compared radiation response as a function of genotype (Supplementary Fig. S7B); there was a statistically significant difference between cell lines with wild-type and nondisruptive mutations (P = 0.004) and between cell lines with disruptive and nondisruptive mutations (P = 0.01) in TP53. We plotted integral survival values derived from clonogenic (Supplementary Fig. S7C) and high-throughput platform (Supplementary Fig. S7D) as a function of TP53 mRNA level and determined statistically significant correlations, R2 = 0.57 and 0.33; P = 0.001 and 0.01, respectively. We computed a score for TP53 activation using a previously described gene signature independent of the gene set included in ssGSEA (see Materials and Methods) and compared TP53 signature scores with radiation response. High-throughput platform integral survival and TP53 score were significantly correlated, R2 = 0.28, and P = 0.03, indicating that a high TP53 signature score is a reasonable predictor of radiation response (Supplementary Fig. S7E). Taken together, these data indicate that mutation and activation of the TP53 pathway is a significant predictor of radiation resistance in lung SCC and highlights the use of ssGSEA as a radiogenomic tool.
The clonogenic assay has long been considered the most reliable in vitro assay for measuring cell survival after exposure to radiation (45, 46). We have adapted the clonogenic assay to measure radiation response in high-throughput form. We reconstituted clonogenic growth by automated plating coupled with assay miniaturization into a 384-well per plate format. The platform accurately measured radiation survival in lung SCC, closely approximating most radiation parameters obtained from clonogenic survival assays. It also seems to accurately profile lung cell lines from nonsquamous lineages, suggesting that it can be applied broadly. It is not clear that measurement of proliferation at 9 days will be sufficient for the accurate profiling of all cell lines, especially those at the extreme ends of growth rates. Nonetheless, minor adaptations of the platform (i.e., plating density and/or time to readout) should allow for the accurate profiling of a wide range of cell lines.
Compared with lung adenocarcinoma, there have been very few therapeutic advances in lung SCC (47). Recently, greater insight into the genomic landscape of lung SCC has been achieved (20), suggesting marked genomic complexity with frequent alterations in TP53, CDKN2A/RB1, NFE2L2/KEAP1/CUL3, and PI3K/AKT. To leverage cancer genomic data to advance knowledge of radiation tumor biology and therapeutic possibilities, we profiled the majority of lung squamous cell lines available for study. We showed that NFE2L2 mutations leading to pathway activation conferred radiation resistance. NFE2L2 pathway alterations are frequent occurrences in lung SCC, found in 38% of the cell lines we analyzed and 34% of The Cancer Genome Atlas (TCGA) samples (20). In a demonstration of the potential of combining the profiling of cell lines for radiation survival with expression-based databases, we carried out an in silico screen and identified PI3K inhibitors as NRF2 antagonists and radiation sensitizers. Taken together, our data suggest assessing these compounds clinically in genotype-selected populations.
We introduced the use of ssGSEA as a hypothesis-generating computational approach to search for genetic markers and cellular pathways that correlate with radiation response. We identified several pathways previously implicated in radiation response including pathways mediating cell survival, genotoxicity, detoxification, and innate or adaptive immunity. In a demonstration of the use of ssGSEA, we analyzed the role of TP53 mutation in regulating radiation response in lung SCCs. We showed that TP53 missense mutation and pathway activation correlated with radiation resistance, whereas TP53 disruptive mutations correlated with radiation sensitivity, a previously unappreciated distinction in lung SCC. Moreover, these data are consistent with clinical outcomes. In patients with locally advanced non–small cell lung carcinoma treated with radiotherapy alone, mutant TP53 (by directed sequencing of the DNA binding domain of the gene) resulted in a decreased treatment response (48–50).
In summary, we have developed a high-throughput platform that accurately measures radiation survival in vitro and significantly facilitates the study of tumor radiogenomics. We also incorporated ssGSEA and cmap for in silico high-throughput gene pathway and drug discovery. Together, these approaches outline a systematic and comprehensive strategy to identify key genetic correlates of radiation response and potent radiation modifiers whose effect is greatest in patients with specific genomic alterations.
Disclosure of Potential Conflicts of Interest
A provisional patent application has been filed directed to certain work of this article. M. Meyerson received a commercial research grant from Novartis, has ownership interests in Foundation Medicine and patent on EGFR mutation licensed to Laboratory Corporation of America, and is a consultant/advisory board member of Novartis and Foundation medicine. No potential conflicts of interest were disclosed by the other authors.
Conception and design: M.E. Abazeed, D.J. Adams, K.E. Hurov, J.S. Loeffler, P.S. Hammerman, M. Meyerson
Development of methodology: M.E. Abazeed, D.J. Adams, P. Tamayo, A.O. Giacomelli
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.E. Abazeed, A.O. Giacomelli, C. Du, D.F. Fries, S.L. Schreiber
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.E. Abazeed, D.J. Adams, P. Tamayo, C.J. Creighton, D. Sonkin, A.O. Giacomelli, K.-K. Wong, J.P. Mesirov, P.S. Hammerman
Writing, review, and/or revision of the manuscript: M.E. Abazeed, D.J. Adams, K.E. Hurov, P. Tamayo, S.L. Schreiber, M. Meyerson
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.E. Abazeed
Study supervision: M. Meyerson
M.E. Abazeed was supported by NIH training grant 5T32CA009382-30 and by funding from the Harvard Radiation Oncology Program. M. Meyerson was supported by NCI RO1 CA109038. P.S. Hammerman was supported by the Stephen D. and Alice Cutler Investigator Fund and by K08 CA163677. The experiments described in Supplementary Fig. S3 were supported in part by NIH RC2 CA138399-01 (S.L. Schreiber). National Institute of General Medical Sciences provided partial support (GM38627; S.L. Schreiber).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors thank the Novartis Institute for Biomedical Research for support. The authors also thank Y. Yan-Neale, T. Chen, W. Shao, and C. Guy for the generation of stable cell lines and for helpful discussions during the course of this work.
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
- Received June 7, 2013.
- Revision received August 9, 2013.
- Accepted August 13, 2013.
- ©2013 American Association for Cancer Research.